Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance study of olaparib and ceralasertib plus olaparib versus placebo in ovarian cancer
2019-003791-39Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of olaparib, ceralasertib and Placebo-COD Research Private Ltd in ovarian cancer (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival by blinded independent central review according to RECIST 1.1 and Sensitivity analysis of progression-free survival by investigator assessment according to RECIST 1.1. Started Jul 2020; status: completed.
02
Drugs
olaparibceralasertibPlacebo-COD Research Private Ltd
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2019-003791-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003791-39.